Ligand Pharmaceuticals Inc.
LGNDStock
$296.45+138.34%52W
Market Cap$5.96B
P/E47.85x
Div yield—
Beta1.16
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)38.70%
Price vs S&P 500 (4W)15.47%
VGM Score51.51
Market Capitalization$5.96B
P/E Ratio (Annual)47.85x
Earnings Surprise History
Q1 261.63est. 1.85
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.33
4.29
4.29
4.29
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
LGNDLigand Pharmaceuticals Inc. | D | C | B | $296.45 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Ligand Pharmaceuticals is a biopharmaceutical company focused on developing and acquiring drug technologies through strategic partnerships and licensing agreements. The company generates revenue from three primary sources: royalties on commercialized products, licensing and milestone payments, and sales of its proprietary Captisol platform.